Jun 16, 2026 07:00AM
May 19, 2026 07:00AM
May 18, 2026 07:00AM
May 14, 2026 07:01AM
May 14, 2026 07:00AM
May 6, 2026 07:00AM
Apr 29, 2026 07:00AM EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
Apr 16, 2026 04:01PM
Mar 16, 2026 07:00AM
Mar 4, 2026 07:00AM
Mar 2, 2026 07:00AM
Mar 2, 2026 07:00AM
Feb 25, 2026 07:00AM
Feb 24, 2026 07:00AM EyePoint Announces Participation at Upcoming Investor Conferences
Feb 18, 2026 07:00AM
Feb 18, 2026 07:00AM
Feb 17, 2026 07:00AM
Feb 5, 2026 07:00AM
Jan 16, 2026 07:00AM
Jan 7, 2026 09:02AM
Jan 7, 2026 07:03AM EyePoint advances retinal drug trials with 2026 data readouts expected
Jan 7, 2026 07:00AM
Dec 21, 2025 08:00PM
Dec 17, 2025 07:00AM
Dec 16, 2025 07:00AM
Dec 9, 2025 10:49AM
Nov 19, 2025 07:00AM
Nov 19, 2025 07:00AM EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
Nov 17, 2025 07:00AM
Nov 5, 2025 07:00AM
Nov 3, 2025 07:00AM
Oct 29, 2025 07:00AM
Oct 16, 2025 07:00AM
Oct 14, 2025 10:43PM
Oct 14, 2025 10:43PM EyePoint Announces Pricing of Public Offering
Oct 14, 2025 04:35PM
Oct 14, 2025 04:35PM
Oct 14, 2025 04:01PM
Oct 14, 2025 04:01PM
Sep 16, 2025 07:00AM
Aug 26, 2025 07:00AM
Aug 18, 2025 04:01PM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 6, 2025 07:30AM
Aug 6, 2025 07:00AM
Jul 30, 2025 07:00AM
Jul 29, 2025 07:00AM
Jul 29, 2025 07:00AM
Jul 16, 2025 07:00AM
Jun 16, 2025 07:00AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 28, 2025 04:01PM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All